05:04:15 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



News for U:XFOR from 2023-03-30 to 2024-03-29 - 30 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-21 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
2024-03-12 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
2024-03-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚  Rule 5635(c)(4)
2023-12-09 12:00U:XFORNews ReleaseX4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
2023-12-04 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-10 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
2023-11-09 06:01U:XFORNews ReleaseX4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and ‚  Provides Corporate Updates
2023-11-02 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
2023-11-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-31 08:00U:XFORNews ReleaseX4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
2023-10-18 08:00U:XFORNews ReleaseX4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
2023-10-02 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚  Rule 5635(c)(4)
2023-09-19 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
2023-09-06 08:00U:XFORNews ReleaseX4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-09-05 08:00U:XFORNews ReleaseX4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
2023-09-01 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-10 06:05U:XFORNews ReleaseX4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
2023-08-08 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
2023-08-03 08:00U:XFORNews ReleaseX4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
2023-08-02 08:01U:XFORNews ReleaseX4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
2023-06-30 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚  Rule 5635(c)(4)
2023-06-13 08:00U:XFORNews ReleaseX4 Pharmaceuticals Expected to Join Russell 3000 ‚ ® Index
2023-06-02 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚  Rule 5635(c)(4)
2023-05-16 16:01U:XFORNews ReleaseX4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
2023-05-16 08:30U:XFORNews ReleaseX4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
2023-05-04 06:05U:XFORNews ReleaseX4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
2023-04-26 08:01U:XFORNews ReleaseX4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
2023-04-12 08:00U:XFORNews ReleaseX4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
2023-04-04 16:05U:XFORNews ReleaseX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚  Rule 5635(c)(4)